Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Desflurane
- Accession Number
- DB01189 (APRD00907)
- Type
- Small Molecule
- Groups
- Approved
- Description
Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anaesthesia. Volatile agents such as desflurane may activate GABA channels and hyperpolarize cell membranes. In addition, they may inhibit certain calcium channels and therefore prevent release of neurotransmitters and inhibit glutamate channels. Volatile anesthetics easily partition into cellular membranes and could expand the volume of the cell membrane and subsequently distort channels necessary for sodium ion flux and the development of action potentials necessary for synaptic transmission. Desflurane preconditions human myocardium against ischemia through activation of mitochondrial K(ATP) channels, adenosine A1 receptor, and alpha and beta adrenoceptors.
- Structure
Structure for Desflurane (DB01189)
- Synonyms
- (+-)-2-Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
- 1,1,1,2-Tetrafluoro-2-(difluoromethoxy)ethane
- Desflurane
- Desflurano
- Desfluranum
- Difluoromethyl 1,2,2,2-tetrafluoroethyl ether
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Suprane Liquid 240 mL/240mL Respiratory (inhalation) Baxter Laboratories 1992-09-18 Not applicable US 
Suprane Liquid 100 % Respiratory (inhalation) Baxter Laboratories 1996-12-23 Not applicable Canada 
Suprane Liquid 240 mL/240mL Respiratory (inhalation) Baxter Laboratories 1992-09-18 Not applicable US Suprane Liquid 240 mL/240mL Respiratory (inhalation) General Injectables & Vaccines 2012-04-25 Not applicable US Suprane Liquid 240 mL/240mL Respiratory (inhalation) Baxter Laboratories 1992-09-18 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Desflurane Liquid 240 mL/240mL Respiratory (inhalation) Sandoz 2018-02-26 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Suprane Desflurane (1.5 g/1mL) Liquid Respiratory (inhalation) Baxter Healthcare Corporation 2006-08-14 2006-08-14 US - International/Other Brands
- Suprane
- Categories
- UNII
- CRS35BZ94Q
- CAS number
- 57041-67-5
- Weight
- Average: 168.0378
Monoisotopic: 168.000983916 - Chemical Formula
- C3H2F6O
- InChI Key
- DPYMFVXJLLWWEU-UHFFFAOYSA-N
- InChI
- InChI=1S/C3H2F6O/c4-1(3(7,8)9)10-2(5)6/h1-2H
- IUPAC Name
- 2-(difluoromethoxy)-1,1,1,2-tetrafluoroethane
- SMILES
- FC(F)OC(F)C(F)(F)F
Pharmacology
- Indication
For use as an inhalation agent for induction and/or maintenance of anesthesia for inpatient and outpatient surgery in adults.
- Associated Therapies
- Pharmacodynamics
Desflurane is a general inhalation anesthetic. It induces muscle relaxation and reduces pains sensitivity by altering tissue excitability. It does so by decreasing the extent of gap junction mediated cell-cell coupling and altering the activity of the channels that underlie the action potential.
- Mechanism of action
Desflurane induces a reduction in junctional conductance by decreasing gap junction channel opening times and increasing gap junction channel closing times. Desflurane also activates calcium dependent ATPase in the sarcoplasmic reticulum by increasing the fluidity of the lipid membrane. It also appears to bind the D subunit of ATP synthase and NADH dehydogenase. Desflurane also binds to and agonizes the GABA receptor, the large conductance Ca2+ activated potassium channel, the glycine receptors, and antagonizes the glutamate receptors.
Target Actions Organism AGABA-A receptor (anion channel) positive allosteric modulatorHuman AGlycine receptor subunit alpha-1 agonistHuman AGlutamate receptor 1 antagonistHuman APotassium voltage-gated channel subfamily A member 1 inducerHuman ACalcium-transporting ATPase type 2C member 1 inhibitorHuman UATP synthase subunit delta, mitochondrial other/unknownHuman UNADH-ubiquinone oxidoreductase chain 1 unknownHuman - Absorption
Rapidly absorbed into the circulation via the lungs following inhalation.
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
Minimally biotransformed in the liver in humans (approximately 0.02% of the quantity absorbed).
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
Interacting Gene/Enzyme Allele name Genotype(s) Defining Change(s) Type(s) Description Details Voltage-dependent L-type calcium channel subunit alpha-1S --- Not Available c.3257G>A / c.520C>T ADR Inferred Malignant hyperthermia. Details Ryanodine receptor 1 --- Not Available c.103T>C / c.487C>T … show all ADR Inferred Malignant hyperthermia. Details
Interactions
- Drug Interactions
Drug Interaction Drug group 7-Nitroindazole The risk or severity of adverse effects can be increased when Desflurane is combined with 7-Nitroindazole. Experimental Acebutolol The risk or severity of adverse effects can be increased when Desflurane is combined with Acebutolol. Approved, Investigational Acepromazine The risk or severity of adverse effects can be increased when Desflurane is combined with Acepromazine. Approved, Vet Approved Aceprometazine The risk or severity of adverse effects can be increased when Desflurane is combined with Aceprometazine. Approved Adipiplon The risk or severity of adverse effects can be increased when Desflurane is combined with Adipiplon. Investigational Agomelatine The risk or severity of adverse effects can be increased when Desflurane is combined with Agomelatine. Approved, Investigational Alaproclate The risk or severity of adverse effects can be increased when Desflurane is combined with Alaproclate. Experimental Aldesleukin The risk or severity of adverse effects can be increased when Desflurane is combined with Aldesleukin. Approved Alfaxalone The risk or severity of adverse effects can be increased when Desflurane is combined with Alfaxalone. Vet Approved Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Desflurane. Approved, Illicit Alimemazine The risk or severity of adverse effects can be increased when Desflurane is combined with Alimemazine. Approved, Vet Approved Aliskiren The risk or severity of adverse effects can be increased when Desflurane is combined with Aliskiren. Approved, Investigational Allopregnanolone The risk or severity of adverse effects can be increased when Desflurane is combined with Allopregnanolone. Investigational Alphacetylmethadol The risk or severity of adverse effects can be increased when Desflurane is combined with Alphacetylmethadol. Experimental, Illicit Alphaprodine The risk or severity of adverse effects can be increased when Desflurane is combined with Alphaprodine. Illicit Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Desflurane. Approved, Illicit, Investigational Amifostine The risk or severity of adverse effects can be increased when Amifostine is combined with Desflurane. Approved, Investigational Amikacin The risk or severity of adverse effects can be increased when Desflurane is combined with Amikacin. Approved, Investigational, Vet Approved Amiloride The risk or severity of adverse effects can be increased when Desflurane is combined with Amiloride. Approved Amiodarone The risk or severity of QTc prolongation can be increased when Desflurane is combined with Amiodarone. Approved, Investigational Amisulpride The risk or severity of adverse effects can be increased when Desflurane is combined with Amisulpride. Approved, Investigational Amitriptyline The risk or severity of adverse effects can be increased when Desflurane is combined with Amitriptyline. Approved Amlodipine The risk or severity of adverse effects can be increased when Desflurane is combined with Amlodipine. Approved Amobarbital The risk or severity of adverse effects can be increased when Desflurane is combined with Amobarbital. Approved, Illicit Amoxapine The risk or severity of adverse effects can be increased when Desflurane is combined with Amoxapine. Approved Amperozide The risk or severity of adverse effects can be increased when Desflurane is combined with Amperozide. Experimental Amphetamine The risk or severity of adverse effects can be increased when Desflurane is combined with Amphetamine. Approved, Illicit, Investigational Amphotericin B The risk or severity of adverse effects can be increased when Amphotericin B is combined with Desflurane. Approved, Investigational Amyl Nitrite The risk or severity of adverse effects can be increased when Desflurane is combined with Amyl Nitrite. Approved Anagrelide Desflurane may increase the QTc-prolonging activities of Anagrelide. Approved Apomorphine The risk or severity of adverse effects can be increased when Apomorphine is combined with Desflurane. Approved, Investigational Apraclonidine The risk or severity of adverse effects can be increased when Desflurane is combined with Apraclonidine. Approved Aripiprazole Aripiprazole may increase the hypotensive activities of Desflurane. Approved, Investigational Arotinolol The risk or severity of adverse effects can be increased when Arotinolol is combined with Desflurane. Investigational Arsenic trioxide Desflurane may increase the QTc-prolonging activities of Arsenic trioxide. Approved, Investigational Artemether Desflurane may increase the QTc-prolonging activities of Artemether. Approved Asenapine Desflurane may increase the QTc-prolonging activities of Asenapine. Approved Atenolol The risk or severity of adverse effects can be increased when Desflurane is combined with Atenolol. Approved Atracurium besylate Desflurane may increase the neuromuscular blocking activities of Atracurium besylate. Approved Azaperone The risk or severity of adverse effects can be increased when Desflurane is combined with Azaperone. Investigational, Vet Approved Azelastine Desflurane may increase the central nervous system depressant (CNS depressant) activities of Azelastine. Approved Azilsartan medoxomil The risk or severity of adverse effects can be increased when Desflurane is combined with Azilsartan medoxomil. Approved, Investigational Azithromycin Desflurane may increase the QTc-prolonging activities of Azithromycin. Approved Baclofen The risk or severity of adverse effects can be increased when Desflurane is combined with Baclofen. Approved Barbexaclone Barbexaclone may increase the hypotensive activities of Desflurane. Experimental Barbital The risk or severity of adverse effects can be increased when Desflurane is combined with Barbital. Illicit Barnidipine The risk or severity of adverse effects can be increased when Barnidipine is combined with Desflurane. Approved Bedaquiline Desflurane may increase the QTc-prolonging activities of Bedaquiline. Approved Benazepril The risk or severity of adverse effects can be increased when Desflurane is combined with Benazepril. Approved, Investigational Bendroflumethiazide The risk or severity of adverse effects can be increased when Desflurane is combined with Bendroflumethiazide. Approved Benperidol The risk or severity of adverse effects can be increased when Desflurane is combined with Benperidol. Approved, Investigational Benzatropine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Benzatropine. Approved Benzphetamine The risk or severity of adverse effects can be increased when Desflurane is combined with Benzphetamine. Approved, Illicit Benzyl alcohol The risk or severity of adverse effects can be increased when Desflurane is combined with Benzyl alcohol. Approved Bepridil The risk or severity of QTc prolongation can be increased when Desflurane is combined with Bepridil. Approved, Withdrawn Betaxolol The risk or severity of QTc prolongation can be increased when Desflurane is combined with Betaxolol. Approved, Investigational Bisoprolol The risk or severity of adverse effects can be increased when Desflurane is combined with Bisoprolol. Approved Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Desflurane. Approved, Investigational Botulinum Toxin Type A The risk or severity of adverse effects can be increased when Desflurane is combined with Botulinum Toxin Type A. Approved, Investigational Botulinum Toxin Type B The risk or severity of adverse effects can be increased when Desflurane is combined with Botulinum Toxin Type B. Approved, Investigational Bretylium The risk or severity of adverse effects can be increased when Desflurane is combined with Bretylium. Approved Brexpiprazole The risk or severity of adverse effects can be increased when Desflurane is combined with Brexpiprazole. Approved, Investigational Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved Bromazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Bromazepam. Approved, Illicit, Investigational Bromisoval The risk or severity of adverse effects can be increased when Desflurane is combined with Bromisoval. Experimental Bromocriptine The risk or severity of adverse effects can be increased when Desflurane is combined with Bromocriptine. Approved, Investigational Bromperidol The risk or severity of adverse effects can be increased when Desflurane is combined with Bromperidol. Approved, Investigational Brompheniramine The risk or severity of adverse effects can be increased when Desflurane is combined with Brompheniramine. Approved Brotizolam The risk or severity of adverse effects can be increased when Desflurane is combined with Brotizolam. Approved, Investigational, Withdrawn Bumetanide The risk or severity of adverse effects can be increased when Desflurane is combined with Bumetanide. Approved Bupivacaine The risk or severity of adverse effects can be increased when Desflurane is combined with Bupivacaine. Approved, Investigational Buprenorphine Desflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Approved, Illicit, Investigational, Vet Approved Bupropion The risk or severity of adverse effects can be increased when Desflurane is combined with Bupropion. Approved Buspirone The risk or severity of adverse effects can be increased when Buspirone is combined with Desflurane. Approved, Investigational Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Desflurane. Approved, Illicit Butacaine The risk or severity of adverse effects can be increased when Desflurane is combined with Butacaine. Vet Approved Butalbital The risk or severity of adverse effects can be increased when Desflurane is combined with Butalbital. Approved, Illicit Butamben The risk or severity of adverse effects can be increased when Desflurane is combined with Butamben. Approved, Withdrawn Butethal The risk or severity of adverse effects can be increased when Desflurane is combined with Butethal. Approved, Illicit Butorphanol The risk or severity of adverse effects can be increased when Butorphanol is combined with Desflurane. Approved, Illicit, Vet Approved Canagliflozin The risk or severity of adverse effects can be increased when Desflurane is combined with Canagliflozin. Approved Candesartan cilexetil The risk or severity of adverse effects can be increased when Desflurane is combined with Candesartan cilexetil. Approved Canertinib The risk or severity of adverse effects can be increased when Desflurane is combined with Canertinib. Investigational Captopril The risk or severity of adverse effects can be increased when Desflurane is combined with Captopril. Approved Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Desflurane. Approved, Investigational Carbetocin The risk or severity of adverse effects can be increased when Carbetocin is combined with Desflurane. Approved, Investigational Carbinoxamine The risk or severity of adverse effects can be increased when Desflurane is combined with Carbinoxamine. Approved Carfentanil The risk or severity of adverse effects can be increased when Desflurane is combined with Carfentanil. Illicit, Investigational, Vet Approved Carisoprodol The risk or severity of adverse effects can be increased when Desflurane is combined with Carisoprodol. Approved Carteolol The risk or severity of adverse effects can be increased when Desflurane is combined with Carteolol. Approved Carvedilol The risk or severity of adverse effects can be increased when Desflurane is combined with Carvedilol. Approved, Investigational Ceritinib Desflurane may increase the QTc-prolonging activities of Ceritinib. Approved Cetirizine The risk or severity of adverse effects can be increased when Desflurane is combined with Cetirizine. Approved Chloral hydrate The risk or severity of adverse effects can be increased when Desflurane is combined with Chloral hydrate. Approved, Illicit, Investigational, Vet Approved Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Desflurane. Approved, Illicit, Investigational Chlormezanone The risk or severity of adverse effects can be increased when Desflurane is combined with Chlormezanone. Approved, Investigational, Withdrawn Chloroprocaine The risk or severity of adverse effects can be increased when Desflurane is combined with Chloroprocaine. Approved Chloroquine Desflurane may increase the QTc-prolonging activities of Chloroquine. Approved, Investigational, Vet Approved Chlorothiazide The risk or severity of adverse effects can be increased when Desflurane is combined with Chlorothiazide. Approved, Vet Approved Chlorphenamine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Chlorphenamine. Approved Chlorpromazine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Chlorpromazine. Approved, Investigational, Vet Approved Chlorprothixene The risk or severity of adverse effects can be increased when Desflurane is combined with Chlorprothixene. Approved, Investigational, Withdrawn Chlorthalidone The risk or severity of adverse effects can be increased when Desflurane is combined with Chlorthalidone. Approved Chlorzoxazone The risk or severity of adverse effects can be increased when Desflurane is combined with Chlorzoxazone. Approved Cilazapril The risk or severity of adverse effects can be increased when Desflurane is combined with Cilazapril. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Desflurane. Approved, Investigational Cinchocaine The risk or severity of adverse effects can be increased when Desflurane is combined with Cinchocaine. Approved, Vet Approved Cinnarizine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Cinnarizine. Approved, Investigational Ciprofloxacin The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ciprofloxacin. Approved, Investigational Cisapride Desflurane may increase the QTc-prolonging activities of Cisapride. Approved, Investigational, Withdrawn Citalopram Desflurane may increase the QTc-prolonging activities of Citalopram. Approved Clarithromycin Desflurane may increase the QTc-prolonging activities of Clarithromycin. Approved Clemastine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Clemastine. Approved, Investigational Clevidipine The risk or severity of adverse effects can be increased when Desflurane is combined with Clevidipine. Approved, Investigational Clidinium The risk or severity of adverse effects can be increased when Desflurane is combined with Clidinium. Approved Clindamycin The risk or severity of adverse effects can be increased when Desflurane is combined with Clindamycin. Approved, Vet Approved Clobazam The risk or severity of adverse effects can be increased when Desflurane is combined with Clobazam. Approved, Illicit Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Desflurane. Approved, Investigational clomethiazole The risk or severity of adverse effects can be increased when Desflurane is combined with clomethiazole. Investigational Clomipramine The risk or severity of adverse effects can be increased when Clomipramine is combined with Desflurane. Approved, Investigational, Vet Approved Clonazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Clonazepam. Approved, Illicit Clonidine The risk or severity of adverse effects can be increased when Desflurane is combined with Clonidine. Approved Clopenthixol The risk or severity of adverse effects can be increased when Desflurane is combined with Clopenthixol. Experimental Clorazepate The risk or severity of adverse effects can be increased when Clorazepate is combined with Desflurane. Approved, Illicit Clothiapine The risk or severity of adverse effects can be increased when Desflurane is combined with Clothiapine. Experimental Clozapine The risk or severity of adverse effects can be increased when Clozapine is combined with Desflurane. Approved Cocaine The risk or severity of adverse effects can be increased when Desflurane is combined with Cocaine. Approved, Illicit Codeine The risk or severity of adverse effects can be increased when Codeine is combined with Desflurane. Approved, Illicit Conivaptan The risk or severity of adverse effects can be increased when Conivaptan is combined with Desflurane. Approved, Investigational Crizotinib Desflurane may increase the QTc-prolonging activities of Crizotinib. Approved Cyclizine The risk or severity of adverse effects can be increased when Desflurane is combined with Cyclizine. Approved Cyclobenzaprine The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desflurane. Approved Cyclopropane The risk or severity of adverse effects can be increased when Desflurane is combined with Cyclopropane. Experimental Cyclosporine The risk or severity of adverse effects can be increased when Desflurane is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproheptadine The risk or severity of adverse effects can be increased when Desflurane is combined with Cyproheptadine. Approved Dantrolene The risk or severity of adverse effects can be increased when Desflurane is combined with Dantrolene. Approved, Investigational Dapagliflozin The risk or severity of adverse effects can be increased when Desflurane is combined with Dapagliflozin. Approved Dapiprazole The risk or severity of adverse effects can be increased when Desflurane is combined with Dapiprazole. Approved Dapoxetine The risk or severity of adverse effects can be increased when Desflurane is combined with Dapoxetine. Investigational Deramciclane The risk or severity of adverse effects can be increased when Desflurane is combined with Deramciclane. Investigational Desipramine The risk or severity of adverse effects can be increased when Desflurane is combined with Desipramine. Approved, Investigational Desloratadine The risk or severity of adverse effects can be increased when Desflurane is combined with Desloratadine. Approved, Investigational Desvenlafaxine The risk or severity of adverse effects can be increased when Desflurane is combined with Desvenlafaxine. Approved, Investigational Detomidine The risk or severity of adverse effects can be increased when Desflurane is combined with Detomidine. Vet Approved Dexbrompheniramine The risk or severity of adverse effects can be increased when Desflurane is combined with Dexbrompheniramine. Approved Dexmedetomidine The risk or severity of adverse effects can be increased when Desflurane is combined with Dexmedetomidine. Approved, Vet Approved Dextromethorphan The risk or severity of adverse effects can be increased when Desflurane is combined with Dextromethorphan. Approved Dextromoramide The risk or severity of adverse effects can be increased when Desflurane is combined with Dextromoramide. Experimental, Illicit Dextropropoxyphene The risk or severity of adverse effects can be increased when Desflurane is combined with Dextropropoxyphene. Approved, Illicit, Investigational, Withdrawn Dezocine The risk or severity of adverse effects can be increased when Desflurane is combined with Dezocine. Approved, Investigational Diazepam The risk or severity of adverse effects can be increased when Diazepam is combined with Desflurane. Approved, Illicit, Investigational, Vet Approved Diclofenamide The risk or severity of adverse effects can be increased when Desflurane is combined with Diclofenamide. Approved, Investigational Diethyl ether The risk or severity of adverse effects can be increased when Desflurane is combined with Diethyl ether. Experimental Difenoxin The risk or severity of adverse effects can be increased when Desflurane is combined with Difenoxin. Approved, Illicit Dihydrocodeine The risk or severity of adverse effects can be increased when Desflurane is combined with Dihydrocodeine. Approved, Illicit Dihydroetorphine The risk or severity of adverse effects can be increased when Desflurane is combined with Dihydroetorphine. Experimental, Illicit Dihydromorphine The risk or severity of adverse effects can be increased when Desflurane is combined with Dihydromorphine. Experimental, Illicit Diltiazem The risk or severity of adverse effects can be increased when Desflurane is combined with Diltiazem. Approved, Investigational Dimenhydrinate The risk or severity of QTc prolongation can be increased when Desflurane is combined with Dimenhydrinate. Approved Dinutuximab The risk or severity of adverse effects can be increased when Desflurane is combined with Dinutuximab. Approved, Investigational Diphenhydramine The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Desflurane. Approved, Investigational Diphenoxylate The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Desflurane. Approved, Illicit Dipyridamole The risk or severity of adverse effects can be increased when Desflurane is combined with Dipyridamole. Approved Disopyramide Desflurane may increase the QTc-prolonging activities of Disopyramide. Approved Dixyrazine The risk or severity of adverse effects can be increased when Desflurane is combined with Dixyrazine. Experimental Dofetilide The risk or severity of QTc prolongation can be increased when Desflurane is combined with Dofetilide. Approved, Investigational Dolasetron Desflurane may increase the QTc-prolonging activities of Dolasetron. Approved, Investigational Domperidone Desflurane may increase the QTc-prolonging activities of Domperidone. Approved, Investigational, Vet Approved Dopamine Desflurane may increase the arrhythmogenic activities of Dopamine. Approved Doramectin The risk or severity of adverse effects can be increased when Desflurane is combined with Doramectin. Vet Approved Dotarizine The risk or severity of adverse effects can be increased when Desflurane is combined with Dotarizine. Investigational Doxazosin The risk or severity of adverse effects can be increased when Desflurane is combined with Doxazosin. Approved Doxepin The risk or severity of adverse effects can be increased when Desflurane is combined with Doxepin. Approved, Investigational Doxycycline The risk or severity of adverse effects can be increased when Desflurane is combined with Doxycycline. Approved, Investigational, Vet Approved Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved, Vet Approved DPDPE The risk or severity of adverse effects can be increased when Desflurane is combined with DPDPE. Experimental Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved, Illicit Dronedarone Desflurane may increase the QTc-prolonging activities of Dronedarone. Approved Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved, Vet Approved Drotebanol The risk or severity of adverse effects can be increased when Desflurane is combined with Drotebanol. Experimental, Illicit Duloxetine Desflurane may increase the orthostatic hypotensive activities of Duloxetine. Approved Dyclonine The risk or severity of adverse effects can be increased when Desflurane is combined with Dyclonine. Approved Ecgonine The risk or severity of adverse effects can be increased when Desflurane is combined with Ecgonine. Experimental, Illicit Ecopipam The risk or severity of adverse effects can be increased when Desflurane is combined with Ecopipam. Investigational Efavirenz The risk or severity of adverse effects can be increased when Desflurane is combined with Efavirenz. Approved, Investigational Efonidipine The risk or severity of adverse effects can be increased when Desflurane is combined with Efonidipine. Approved, Investigational Eliglustat Desflurane may increase the QTc-prolonging activities of Eliglustat. Approved Eltanolone The risk or severity of adverse effects can be increased when Desflurane is combined with Eltanolone. Investigational Empagliflozin The risk or severity of adverse effects can be increased when Desflurane is combined with Empagliflozin. Approved Enalapril The risk or severity of adverse effects can be increased when Desflurane is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when Desflurane is combined with Enalaprilat. Approved Enflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Enflurane. Approved, Investigational, Vet Approved Entacapone The risk or severity of adverse effects can be increased when Desflurane is combined with Entacapone. Approved, Investigational Eperisone The risk or severity of adverse effects can be increased when Desflurane is combined with Eperisone. Approved, Investigational Ephedra Desflurane may increase the arrhythmogenic activities of Ephedra. Approved, Nutraceutical, Withdrawn Ephedrine Ephedrine may increase the arrhythmogenic activities of Desflurane. Approved Epinephrine Desflurane may increase the arrhythmogenic activities of Epinephrine. Approved, Vet Approved Eplerenone The risk or severity of adverse effects can be increased when Desflurane is combined with Eplerenone. Approved Epoprostenol The risk or severity of adverse effects can be increased when Desflurane is combined with Epoprostenol. Approved Eprosartan The risk or severity of adverse effects can be increased when Desflurane is combined with Eprosartan. Approved Erythromycin The risk or severity of QTc prolongation can be increased when Desflurane is combined with Erythromycin. Approved, Investigational, Vet Approved Escitalopram Desflurane may increase the QTc-prolonging activities of Escitalopram. Approved, Investigational Esmolol The risk or severity of adverse effects can be increased when Desflurane is combined with Esmolol. Approved Estazolam The risk or severity of adverse effects can be increased when Desflurane is combined with Estazolam. Approved, Illicit Eszopiclone The risk or severity of adverse effects can be increased when Eszopiclone is combined with Desflurane. Approved, Investigational Etacrynic acid The risk or severity of adverse effects can be increased when Desflurane is combined with Etacrynic acid. Approved, Investigational Ethanol Desflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol. Approved Ethchlorvynol The risk or severity of adverse effects can be increased when Desflurane is combined with Ethchlorvynol. Approved, Illicit, Withdrawn Ethosuximide The risk or severity of adverse effects can be increased when Desflurane is combined with Ethosuximide. Approved Ethotoin The risk or severity of adverse effects can be increased when Desflurane is combined with Ethotoin. Approved Ethyl carbamate The risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl carbamate. Withdrawn Ethyl chloride The risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl chloride. Approved, Experimental, Investigational Ethyl loflazepate The risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl loflazepate. Approved, Illicit Ethylmorphine The risk or severity of adverse effects can be increased when Desflurane is combined with Ethylmorphine. Approved, Illicit Etidocaine The risk or severity of adverse effects can be increased when Desflurane is combined with Etidocaine. Approved Etifoxine The risk or severity of adverse effects can be increased when Desflurane is combined with Etifoxine. Investigational, Withdrawn Etizolam The risk or severity of adverse effects can be increased when Desflurane is combined with Etizolam. Approved Etomidate The risk or severity of adverse effects can be increased when Desflurane is combined with Etomidate. Approved Etoperidone The risk or severity of adverse effects can be increased when Desflurane is combined with Etoperidone. Withdrawn Etorphine The risk or severity of adverse effects can be increased when Desflurane is combined with Etorphine. Illicit, Vet Approved Ezogabine The risk or severity of adverse effects can be increased when Desflurane is combined with Ezogabine. Approved, Investigational Famotidine The risk or severity of QTc prolongation can be increased when Famotidine is combined with Desflurane. Approved Felbamate The risk or severity of adverse effects can be increased when Desflurane is combined with Felbamate. Approved Felodipine The risk or severity of adverse effects can be increased when Desflurane is combined with Felodipine. Approved, Investigational Fencamfamine The risk or severity of adverse effects can be increased when Desflurane is combined with Fencamfamine. Approved, Illicit, Withdrawn Fenoldopam The risk or severity of adverse effects can be increased when Desflurane is combined with Fenoldopam. Approved Fentanyl The risk or severity of adverse effects can be increased when Fentanyl is combined with Desflurane. Approved, Illicit, Investigational, Vet Approved Fexofenadine The risk or severity of adverse effects can be increased when Desflurane is combined with Fexofenadine. Approved, Investigational Fimasartan The risk or severity of adverse effects can be increased when Desflurane is combined with Fimasartan. Approved, Investigational Flecainide Desflurane may increase the QTc-prolonging activities of Flecainide. Approved, Withdrawn Flibanserin The risk or severity of adverse effects can be increased when Desflurane is combined with Flibanserin. Approved, Investigational Fluanisone The risk or severity of adverse effects can be increased when Desflurane is combined with Fluanisone. Experimental Fluconazole The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Desflurane. Approved, Investigational Fludiazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Fludiazepam. Approved, Illicit Flunarizine The risk or severity of adverse effects can be increased when Desflurane is combined with Flunarizine. Approved Flunitrazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Flunitrazepam. Approved, Illicit Fluorouracil The risk or severity of QTc prolongation can be increased when Desflurane is combined with Fluorouracil. Approved Fluoxetine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Fluoxetine. Approved, Vet Approved Flupentixol Desflurane may increase the QTc-prolonging activities of Flupentixol. Approved, Investigational, Withdrawn Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Desflurane. Approved Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Desflurane. Approved, Illicit, Investigational Fluspirilene The risk or severity of adverse effects can be increased when Desflurane is combined with Fluspirilene. Approved, Investigational Fluticasone propionate The risk or severity of adverse effects can be increased when Desflurane is combined with Fluticasone propionate. Approved Fluvoxamine The risk or severity of adverse effects can be increased when Desflurane is combined with Fluvoxamine. Approved, Investigational Formoterol Desflurane may increase the arrhythmogenic activities of Formoterol. Approved, Investigational Fosinopril The risk or severity of adverse effects can be increased when Desflurane is combined with Fosinopril. Approved Fosphenytoin The risk or severity of adverse effects can be increased when Desflurane is combined with Fosphenytoin. Approved, Investigational Fospropofol The risk or severity of adverse effects can be increased when Desflurane is combined with Fospropofol. Approved, Illicit, Investigational Furosemide The risk or severity of adverse effects can be increased when Desflurane is combined with Furosemide. Approved, Vet Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Desflurane. Approved, Investigational Gabapentin enacarbil The risk or severity of adverse effects can be increased when Desflurane is combined with Gabapentin Enacarbil. Approved, Investigational Gadobenic acid Desflurane may increase the QTc-prolonging activities of Gadobenic acid. Approved, Investigational Gamma hydroxybutyric acid The risk or severity of adverse effects can be increased when Desflurane is combined with Gamma Hydroxybutyric Acid. Approved, Illicit, Investigational Gemifloxacin Desflurane may increase the QTc-prolonging activities of Gemifloxacin. Approved, Investigational Gentamicin The risk or severity of adverse effects can be increased when Desflurane is combined with Gentamicin. Approved, Vet Approved Gepirone The risk or severity of adverse effects can be increased when Desflurane is combined with Gepirone. Investigational Glutethimide The risk or severity of adverse effects can be increased when Desflurane is combined with Glutethimide. Approved, Illicit Goserelin The risk or severity of QTc prolongation can be increased when Desflurane is combined with Goserelin. Approved Granisetron Desflurane may increase the QTc-prolonging activities of Granisetron. Approved, Investigational Guanfacine The risk or severity of adverse effects can be increased when Desflurane is combined with Guanfacine. Approved, Investigational Halazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Halazepam. Approved, Illicit, Withdrawn Haloperidol The risk or severity of QTc prolongation can be increased when Desflurane is combined with Haloperidol. Approved Halothane The risk or severity of adverse effects can be increased when Desflurane is combined with Halothane. Approved, Vet Approved Heroin The risk or severity of adverse effects can be increased when Desflurane is combined with Heroin. Approved, Illicit, Investigational Hexobarbital The risk or severity of adverse effects can be increased when Desflurane is combined with Hexobarbital. Approved Hydralazine The risk or severity of adverse effects can be increased when Desflurane is combined with Hydralazine. Approved Hydrochlorothiazide The risk or severity of adverse effects can be increased when Desflurane is combined with Hydrochlorothiazide. Approved, Vet Approved Hydrocodone Desflurane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. Approved, Illicit, Investigational Hydroflumethiazide The risk or severity of adverse effects can be increased when Desflurane is combined with Hydroflumethiazide. Approved, Investigational Hydromorphone The risk or severity of adverse effects can be increased when Hydromorphone is combined with Desflurane. Approved, Illicit Hydroxychloroquine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Hydroxychloroquine. Approved Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved Ibandronate The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Desflurane. Approved, Investigational Ibutilide Desflurane may increase the QTc-prolonging activities of Ibutilide. Approved Iloperidone Desflurane may increase the QTc-prolonging activities of Iloperidone. Approved Iloprost The risk or severity of adverse effects can be increased when Desflurane is combined with Iloprost. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when Desflurane is combined with Imidapril. Investigational Imipramine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Imipramine. Approved Indalpine The risk or severity of adverse effects can be increased when Desflurane is combined with Indalpine. Investigational, Withdrawn Indapamide The risk or severity of adverse effects can be increased when Desflurane is combined with Indapamide. Approved Indiplon The risk or severity of adverse effects can be increased when Desflurane is combined with Indiplon. Investigational Indoramin The risk or severity of adverse effects can be increased when Desflurane is combined with Indoramin. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Desflurane is combined with Irbesartan. Approved, Investigational Isocarboxazid The risk or severity of adverse effects can be increased when Desflurane is combined with Isocarboxazid. Approved Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Desflurane. Approved, Vet Approved Isoprenaline Desflurane may increase the arrhythmogenic activities of Isoprenaline. Approved, Investigational Isosorbide dinitrate The risk or severity of adverse effects can be increased when Desflurane is combined with Isosorbide Dinitrate. Approved, Investigational Isosorbide Mononitrate The risk or severity of adverse effects can be increased when Desflurane is combined with Isosorbide Mononitrate. Approved Isoxsuprine The risk or severity of adverse effects can be increased when Desflurane is combined with Isoxsuprine. Approved, Withdrawn Isradipine The risk or severity of adverse effects can be increased when Desflurane is combined with Isradipine. Approved, Investigational Itraconazole The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Desflurane. Approved, Investigational Ketamine The risk or severity of adverse effects can be increased when Desflurane is combined with Ketamine. Approved, Vet Approved Ketazolam The risk or severity of adverse effects can be increased when Desflurane is combined with Ketazolam. Approved Ketobemidone The risk or severity of adverse effects can be increased when Desflurane is combined with Ketobemidone. Approved, Investigational Ketotifen The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ketotifen. Approved L-Tryptophan The risk or severity of adverse effects can be increased when Desflurane is combined with L-Tryptophan. Approved, Nutraceutical, Withdrawn Labetalol The risk or severity of adverse effects can be increased when Desflurane is combined with Labetalol. Approved Lacidipine Desflurane may increase the hypotensive activities of Lacidipine. Approved, Investigational Lamotrigine The risk or severity of adverse effects can be increased when Desflurane is combined with Lamotrigine. Approved, Investigational Lenvatinib Desflurane may increase the QTc-prolonging activities of Lenvatinib. Approved, Investigational Lercanidipine The risk or severity of adverse effects can be increased when Desflurane is combined with Lercanidipine. Approved, Investigational Leuprolide The risk or severity of QTc prolongation can be increased when Desflurane is combined with Leuprolide. Approved, Investigational Levetiracetam The risk or severity of adverse effects can be increased when Desflurane is combined with Levetiracetam. Approved, Investigational Levobunolol The risk or severity of adverse effects can be increased when Desflurane is combined with Levobunolol. Approved Levobupivacaine The risk or severity of adverse effects can be increased when Desflurane is combined with Levobupivacaine. Approved, Investigational Levocabastine The risk or severity of adverse effects can be increased when Desflurane is combined with Levocabastine. Approved, Investigational Levocetirizine The risk or severity of adverse effects can be increased when Desflurane is combined with Levocetirizine. Approved Levodopa The risk or severity of adverse effects can be increased when Desflurane is combined with Levodopa. Approved Levodopa The risk or severity of hypotension and orthostatic hypotension can be increased when Desflurane is combined with Levodopa. Approved Levofloxacin Desflurane may increase the QTc-prolonging activities of Levofloxacin. Approved, Investigational Levomethadyl acetate The risk or severity of adverse effects can be increased when Desflurane is combined with Levomethadyl Acetate. Approved, Investigational Levomilnacipran The risk or severity of adverse effects can be increased when Desflurane is combined with Levomilnacipran. Approved, Investigational Levorphanol The risk or severity of adverse effects can be increased when Levorphanol is combined with Desflurane. Approved Levosimendan The risk or severity of adverse effects can be increased when Desflurane is combined with Levosimendan. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when Desflurane is combined with Lisinopril. Approved, Investigational Lithium carbonate The risk or severity of adverse effects can be increased when Desflurane is combined with Lithium carbonate. Approved Lithium cation The risk or severity of adverse effects can be increased when Desflurane is combined with Lithium. Experimental Lofentanil The risk or severity of adverse effects can be increased when Desflurane is combined with Lofentanil. Illicit Lofexidine The therapeutic efficacy of Desflurane can be increased when used in combination with Lofexidine. Approved, Investigational Lopinavir Desflurane may increase the QTc-prolonging activities of Lopinavir. Approved Loprazolam The risk or severity of adverse effects can be increased when Desflurane is combined with Loprazolam. Experimental Loratadine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Loratadine. Approved, Investigational Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Desflurane. Approved Lormetazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Lormetazepam. Approved Losartan The risk or severity of adverse effects can be increased when Desflurane is combined with Losartan. Approved Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Desflurane. Approved Lumefantrine Desflurane may increase the QTc-prolonging activities of Lumefantrine. Approved Lurasidone The risk or severity of adverse effects can be increased when Desflurane is combined with Lurasidone. Approved, Investigational Magnesium carbonate The risk or severity of adverse effects can be increased when Desflurane is combined with Magnesium carbonate. Approved, Investigational Magnesium citrate The risk or severity of adverse effects can be increased when Desflurane is combined with Magnesium citrate. Approved Magnesium hydroxide The risk or severity of adverse effects can be increased when Desflurane is combined with Magnesium hydroxide. Approved, Investigational Magnesium sulfate The therapeutic efficacy of Desflurane can be increased when used in combination with Magnesium sulfate. Approved, Investigational, Vet Approved Magnesium Trisilicate The risk or severity of adverse effects can be increased when Desflurane is combined with Magnesium Trisilicate. Approved Mannitol The risk or severity of adverse effects can be increased when Desflurane is combined with Mannitol. Approved, Investigational Maprotiline The risk or severity of adverse effects can be increased when Desflurane is combined with Maprotiline. Approved, Investigational Mebicar The risk or severity of adverse effects can be increased when Desflurane is combined with Mebicar. Experimental Mecamylamine The risk or severity of adverse effects can be increased when Desflurane is combined with Mecamylamine. Approved, Investigational Meclizine The risk or severity of adverse effects can be increased when Desflurane is combined with Meclizine. Approved Medazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Medazepam. Experimental Medetomidine The risk or severity of adverse effects can be increased when Desflurane is combined with Medetomidine. Vet Approved Melatonin The risk or severity of adverse effects can be increased when Desflurane is combined with Melatonin. Approved, Nutraceutical, Vet Approved Melperone The risk or severity of adverse effects can be increased when Desflurane is combined with Melperone. Approved, Investigational Mepivacaine The risk or severity of adverse effects can be increased when Desflurane is combined with Mepivacaine. Approved, Vet Approved Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Desflurane. Approved, Illicit Meptazinol The risk or severity of adverse effects can be increased when Desflurane is combined with Meptazinol. Experimental Mepyramine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Mepyramine. Approved, Vet Approved Mesoridazine The risk or severity of adverse effects can be increased when Desflurane is combined with Mesoridazine. Approved, Investigational Metaxalone The risk or severity of adverse effects can be increased when Desflurane is combined with Metaxalone. Approved Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Desflurane. Approved Methadyl acetate The risk or severity of adverse effects can be increased when Desflurane is combined with Methadyl Acetate. Approved, Illicit Methapyrilene The risk or severity of adverse effects can be increased when Desflurane is combined with Methapyrilene. Withdrawn Methaqualone The risk or severity of adverse effects can be increased when Desflurane is combined with Methaqualone. Illicit, Withdrawn Methazolamide The risk or severity of adverse effects can be increased when Desflurane is combined with Methazolamide. Approved Methocarbamol The risk or severity of adverse effects can be increased when Desflurane is combined with Methocarbamol. Approved, Vet Approved Methohexital The risk or severity of adverse effects can be increased when Methohexital is combined with Desflurane. Approved Methotrimeprazine Desflurane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. Approved, Investigational Methoxyflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Methoxyflurane. Approved, Investigational, Vet Approved Methsuximide The risk or severity of adverse effects can be increased when Desflurane is combined with Methsuximide. Approved Methyclothiazide The risk or severity of adverse effects can be increased when Desflurane is combined with Methyclothiazide. Approved Methyldopa The risk or severity of adverse effects can be increased when Desflurane is combined with Methyldopa. Approved Methylecgonine The risk or severity of adverse effects can be increased when Desflurane is combined with Methylecgonine. Experimental Methylphenidate Methylphenidate may increase the hypertensive activities of Desflurane. Approved, Investigational Methylphenobarbital The risk or severity of adverse effects can be increased when Desflurane is combined with Methylphenobarbital. Approved Metipranolol The risk or severity of adverse effects can be increased when Desflurane is combined with Metipranolol. Approved Metoclopramide The risk or severity of QTc prolongation can be increased when Desflurane is combined with Metoclopramide. Approved, Investigational Metolazone The risk or severity of adverse effects can be increased when Desflurane is combined with Metolazone. Approved Metoprolol The risk or severity of adverse effects can be increased when Desflurane is combined with Metoprolol. Approved, Investigational Metronidazole The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Desflurane. Approved Metyrosine Desflurane may increase the sedative activities of Metyrosine. Approved Midazolam The risk or severity of adverse effects can be increased when Midazolam is combined with Desflurane. Approved, Illicit Mifepristone Mifepristone may increase the QTc-prolonging activities of Desflurane. Approved, Investigational Milnacipran The risk or severity of adverse effects can be increased when Desflurane is combined with Milnacipran. Approved, Investigational Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved, Investigational Minoxidil The risk or severity of adverse effects can be increased when Desflurane is combined with Minoxidil. Approved, Investigational Mirtazapine Desflurane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. Approved Mivacurium Desflurane may increase the neuromuscular blocking activities of Mivacurium. Approved Moexipril The risk or severity of adverse effects can be increased when Desflurane is combined with Moexipril. Approved Molindone The risk or severity of adverse effects can be increased when Desflurane is combined with Molindone. Approved Morphine The risk or severity of adverse effects can be increased when Morphine is combined with Desflurane. Approved, Investigational Moxifloxacin The risk or severity of QTc prolongation can be increased when Desflurane is combined with Moxifloxacin. Approved, Investigational Moxonidine The risk or severity of adverse effects can be increased when Desflurane is combined with Moxonidine. Approved, Investigational Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved, Investigational Nadolol The risk or severity of adverse effects can be increased when Desflurane is combined with Nadolol. Approved Nalbuphine The risk or severity of adverse effects can be increased when Nalbuphine is combined with Desflurane. Approved Nebivolol The risk or severity of adverse effects can be increased when Desflurane is combined with Nebivolol. Approved, Investigational Nefazodone The risk or severity of adverse effects can be increased when Desflurane is combined with Nefazodone. Approved, Withdrawn Neomycin The risk or severity of adverse effects can be increased when Desflurane is combined with Neomycin. Approved, Vet Approved Nesiritide The risk or severity of adverse effects can be increased when Desflurane is combined with Nesiritide. Approved, Investigational Nicardipine The risk or severity of adverse effects can be increased when Desflurane is combined with Nicardipine. Approved, Investigational Nicorandil Nicorandil may increase the hypotensive activities of Desflurane. Approved, Investigational Nifedipine The risk or severity of adverse effects can be increased when Desflurane is combined with Nifedipine. Approved Nilotinib Desflurane may increase the QTc-prolonging activities of Nilotinib. Approved, Investigational Nilvadipine The risk or severity of adverse effects can be increased when Desflurane is combined with Nilvadipine. Approved, Investigational Nimodipine The risk or severity of adverse effects can be increased when Desflurane is combined with Nimodipine. Approved, Investigational Nisoldipine The risk or severity of adverse effects can be increased when Desflurane is combined with Nisoldipine. Approved Nitrazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrazepam. Approved Nitrendipine The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrendipine. Approved, Investigational Nitric Oxide The risk or severity of adverse effects can be increased when Desflurane is combined with Nitric Oxide. Approved Nitroglycerin The risk or severity of adverse effects can be increased when Desflurane is combined with Nitroglycerin. Approved, Investigational Nitroprusside The risk or severity of adverse effects can be increased when Desflurane is combined with Nitroprusside. Approved, Investigational Nitrous acid The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrous acid. Approved, Investigational Nitrous oxide The risk or severity of adverse effects can be increased when Desflurane is combined with Nitrous oxide. Approved, Vet Approved Nordazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Nordazepam. Approved Norepinephrine Desflurane may increase the arrhythmogenic activities of Norepinephrine. Approved Norflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Norflurane. Approved, Investigational Normethadone The risk or severity of adverse effects can be increased when Desflurane is combined with Normethadone. Approved, Illicit Nortriptyline The risk or severity of adverse effects can be increased when Desflurane is combined with Nortriptyline. Approved Obinutuzumab The risk or severity of adverse effects can be increased when Desflurane is combined with Obinutuzumab. Approved, Investigational Octreotide The risk or severity of QTc prolongation can be increased when Octreotide is combined with Desflurane. Approved, Investigational Ofloxacin Desflurane may increase the QTc-prolonging activities of Ofloxacin. Approved Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Desflurane. Approved, Investigational Olmesartan The risk or severity of adverse effects can be increased when Desflurane is combined with Olmesartan. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Desflurane is combined with Olopatadine. Approved Ondansetron The risk or severity of QTc prolongation can be increased when Desflurane is combined with Ondansetron. Approved Opium The risk or severity of adverse effects can be increased when Desflurane is combined with Opium. Approved, Illicit Orphenadrine Desflurane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. Approved Osanetant The risk or severity of adverse effects can be increased when Desflurane is combined with Osanetant. Investigational Oxazepam The risk or severity of adverse effects can be increased when Oxazepam is combined with Desflurane. Approved Oxprenolol The risk or severity of adverse effects can be increased when Desflurane is combined with Oxprenolol. Approved Oxybuprocaine The risk or severity of adverse effects can be increased when Desflurane is combined with Oxybuprocaine. Approved, Investigational Oxycodone The risk or severity of adverse effects can be increased when Oxycodone is combined with Desflurane. Approved, Illicit, Investigational Oxymorphone The risk or severity of adverse effects can be increased when Desflurane is combined with Oxymorphone. Approved, Investigational, Vet Approved Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Desflurane. Approved, Vet Approved Paclitaxel The risk or severity of adverse effects can be increased when Desflurane is combined with Paclitaxel. Approved, Vet Approved Paliperidone Desflurane may increase the QTc-prolonging activities of Paliperidone. Approved Panobinostat Desflurane may increase the QTc-prolonging activities of Panobinostat. Approved, Investigational Papaverine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Papaverine. Approved, Investigational Paraldehyde Desflurane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. Approved, Investigational Paromomycin The risk or severity of adverse effects can be increased when Desflurane is combined with Paromomycin. Approved, Investigational Paroxetine The risk or severity of adverse effects can be increased when Desflurane is combined with Paroxetine. Approved, Investigational Pazopanib Desflurane may increase the QTc-prolonging activities of Pazopanib. Approved Penbutolol The risk or severity of adverse effects can be increased when Desflurane is combined with Penbutolol. Approved, Investigational Penfluridol The risk or severity of adverse effects can be increased when Desflurane is combined with Penfluridol. Experimental Pentamidine Desflurane may increase the QTc-prolonging activities of Pentamidine. Approved, Investigational Pentazocine The risk or severity of adverse effects can be increased when Pentazocine is combined with Desflurane. Approved, Vet Approved Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Desflurane. Approved, Investigational, Vet Approved Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved Perazine The risk or severity of adverse effects can be increased when Desflurane is combined with Perazine. Approved, Investigational Perflutren Desflurane may increase the QTc-prolonging activities of Perflutren. Approved Perindopril The risk or severity of adverse effects can be increased when Desflurane is combined with Perindopril. Approved Perospirone The risk or severity of adverse effects can be increased when Desflurane is combined with Perospirone. Approved Perphenazine The risk or severity of adverse effects can be increased when Perphenazine is combined with Desflurane. Approved Pethidine The risk or severity of adverse effects can be increased when Pethidine is combined with Desflurane. Approved Phenazocine The risk or severity of adverse effects can be increased when Desflurane is combined with Phenazocine. Experimental Phenelzine The risk or severity of adverse effects can be increased when Desflurane is combined with Phenelzine. Approved Phenibut The risk or severity of adverse effects can be increased when Desflurane is combined with Phenibut. Experimental Pheniramine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Pheniramine. Approved Phenobarbital Phenobarbital may increase the hypotensive activities of Desflurane. Approved, Investigational Phenoperidine The risk or severity of adverse effects can be increased when Desflurane is combined with Phenoperidine. Experimental Phenoxybenzamine The risk or severity of adverse effects can be increased when Desflurane is combined with Phenoxybenzamine. Approved Phenoxyethanol The risk or severity of adverse effects can be increased when Desflurane is combined with Phenoxyethanol. Approved Phentermine The risk or severity of adverse effects can be increased when Desflurane is combined with Phentermine. Approved, Illicit Phentolamine The risk or severity of adverse effects can be increased when Desflurane is combined with Phentolamine. Approved Phenytoin The risk or severity of adverse effects can be increased when Desflurane is combined with Phenytoin. Approved, Vet Approved Pimozide Desflurane may increase the QTc-prolonging activities of Pimozide. Approved Pindolol The risk or severity of adverse effects can be increased when Desflurane is combined with Pindolol. Approved, Investigational Pipamperone The risk or severity of adverse effects can be increased when Desflurane is combined with Pipamperone. Approved, Investigational Pipotiazine The risk or severity of adverse effects can be increased when Desflurane is combined with Pipotiazine. Approved, Investigational Piritramide The risk or severity of adverse effects can be increased when Desflurane is combined with Piritramide. Approved, Investigational Pizotifen The risk or severity of adverse effects can be increased when Desflurane is combined with Pizotifen. Approved Polymyxin B Sulfate The risk or severity of adverse effects can be increased when Desflurane is combined with Polymyxin B Sulfate. Approved, Vet Approved Pomalidomide The risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide. Approved Pramipexole Desflurane may increase the sedative activities of Pramipexole. Approved, Investigational Prazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Prazepam. Approved, Illicit Prazosin The risk or severity of adverse effects can be increased when Desflurane is combined with Prazosin. Approved Pregabalin The therapeutic efficacy of Desflurane can be increased when used in combination with Pregabalin. Approved, Illicit, Investigational Prilocaine The risk or severity of adverse effects can be increased when Desflurane is combined with Prilocaine. Approved Primaquine Desflurane may increase the QTc-prolonging activities of Primaquine. Approved Primidone Primidone may increase the hypotensive activities of Desflurane. Approved, Vet Approved Procainamide Desflurane may increase the QTc-prolonging activities of Procainamide. Approved Procaine The risk or severity of adverse effects can be increased when Desflurane is combined with Procaine. Approved, Investigational, Vet Approved Prochlorperazine The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Desflurane. Approved, Vet Approved Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Desflurane. Approved, Vet Approved Promethazine The risk or severity of adverse effects can be increased when Desflurane is combined with Promethazine. Approved, Investigational Propafenone The risk or severity of QTc prolongation can be increased when Desflurane is combined with Propafenone. Approved Propanidid The risk or severity of adverse effects can be increased when Desflurane is combined with Propanidid. Experimental Proparacaine The risk or severity of adverse effects can be increased when Desflurane is combined with Proparacaine. Approved, Vet Approved Propericiazine The risk or severity of adverse effects can be increased when Desflurane is combined with Propericiazine. Approved, Investigational Propofol The risk or severity of adverse effects can be increased when Propofol is combined with Desflurane. Approved, Investigational, Vet Approved Propoxycaine The risk or severity of adverse effects can be increased when Desflurane is combined with Propoxycaine. Approved Propranolol The risk or severity of QTc prolongation can be increased when Desflurane is combined with Propranolol. Approved, Investigational Protriptyline The risk or severity of adverse effects can be increased when Desflurane is combined with Protriptyline. Approved Proxibarbal The risk or severity of adverse effects can be increased when Desflurane is combined with Proxibarbal. Experimental PSD502 The risk or severity of adverse effects can be increased when Desflurane is combined with PSD502. Investigational Pyrantel The risk or severity of adverse effects can be increased when Desflurane is combined with Pyrantel. Approved, Vet Approved Quazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Quazepam. Approved, Illicit Quetiapine The risk or severity of QTc prolongation can be increased when Desflurane is combined with Quetiapine. Approved Quinapril The risk or severity of adverse effects can be increased when Desflurane is combined with Quinapril. Approved, Investigational Quinidine Desflurane may increase the QTc-prolonging activities of Quinidine. Approved, Investigational Quinine Desflurane may increase the QTc-prolonging activities of Quinine. Approved Quinisocaine The risk or severity of adverse effects can be increased when Desflurane is combined with Quinisocaine. Experimental Raclopride The risk or severity of adverse effects can be increased when Desflurane is combined with Raclopride. Investigational Ramelteon The risk or severity of adverse effects can be increased when Desflurane is combined with Ramelteon. Approved, Investigational Ramipril The risk or severity of adverse effects can be increased when Desflurane is combined with Ramipril. Approved Rapacuronium Desflurane may increase the neuromuscular blocking activities of Rapacuronium. Approved, Withdrawn Rasagiline The risk or severity of adverse effects can be increased when Desflurane is combined with Rasagiline. Approved Remifentanil The risk or severity of adverse effects can be increased when Remifentanil is combined with Desflurane. Approved Remoxipride The risk or severity of adverse effects can be increased when Desflurane is combined with Remoxipride. Approved, Withdrawn Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Desflurane. Approved, Investigational Riociguat The risk or severity of adverse effects can be increased when Desflurane is combined with Riociguat. Approved Risperidone Desflurane may increase the hypotensive activities of Risperidone. Approved, Investigational Ritanserin The risk or severity of adverse effects can be increased when Desflurane is combined with Ritanserin. Investigational Rizatriptan The risk or severity of adverse effects can be increased when Desflurane is combined with Rizatriptan. Approved Romifidine The risk or severity of adverse effects can be increased when Desflurane is combined with Romifidine. Vet Approved Ropinirole Desflurane may increase the sedative activities of Ropinirole. Approved, Investigational Ropivacaine The risk or severity of adverse effects can be increased when Desflurane is combined with Ropivacaine. Approved Rotigotine Desflurane may increase the sedative activities of Rotigotine. Approved Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Desflurane. Approved Sacubitril The risk or severity of adverse effects can be increased when Desflurane is combined with Sacubitril. Approved Salbutamol The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Desflurane. Approved, Vet Approved Salmeterol The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Desflurane. Approved Saquinavir Desflurane may increase the QTc-prolonging activities of Saquinavir. Approved, Investigational Scopolamine The risk or severity of adverse effects can be increased when Desflurane is combined with Scopolamine. Approved, Investigational Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Desflurane. Approved, Vet Approved Selegiline The risk or severity of adverse effects can be increased when Desflurane is combined with Selegiline. Approved, Investigational, Vet Approved Sepranolone The risk or severity of adverse effects can be increased when Desflurane is combined with Sepranolone. Investigational Sertindole The risk or severity of adverse effects can be increased when Desflurane is combined with Sertindole. Approved, Investigational, Withdrawn Sertraline The risk or severity of adverse effects can be increased when Desflurane is combined with Sertraline. Approved Sevoflurane The risk or severity of adverse effects can be increased when Desflurane is combined with Sevoflurane. Approved, Vet Approved Sodium oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved Sotalol Desflurane may increase the QTc-prolonging activities of Sotalol. Approved Spironolactone The risk or severity of adverse effects can be increased when Desflurane is combined with Spironolactone. Approved Stiripentol The risk or severity of adverse effects can be increased when Desflurane is combined with Stiripentol. Approved Streptokinase The risk or severity of adverse effects can be increased when Desflurane is combined with Streptokinase. Approved, Investigational Succinylcholine The risk or severity of adverse effects can be increased when Desflurane is combined with Succinylcholine. Approved Sufentanil The risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane. Approved, Investigational Sulfisoxazole Desflurane may increase the QTc-prolonging activities of Sulfisoxazole. Approved, Vet Approved Sulpiride The risk or severity of adverse effects can be increased when Desflurane is combined with Sulpiride. Approved, Investigational Sultopride The risk or severity of adverse effects can be increased when Desflurane is combined with Sultopride. Experimental Sumatriptan The risk or severity of adverse effects can be increased when Desflurane is combined with Sumatriptan. Approved, Investigational Suvorexant Desflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Approved, Investigational Tamoxifen The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Desflurane. Approved Tamsulosin The risk or severity of adverse effects can be increased when Desflurane is combined with Tamsulosin. Approved, Investigational Tandospirone The risk or severity of adverse effects can be increased when Desflurane is combined with Tandospirone. Investigational Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Desflurane. Approved Tasimelteon The risk or severity of adverse effects can be increased when Desflurane is combined with Tasimelteon. Approved, Investigational Telavancin Desflurane may increase the QTc-prolonging activities of Telavancin. Approved Telithromycin Desflurane may increase the QTc-prolonging activities of Telithromycin. Approved Telmisartan The risk or severity of adverse effects can be increased when Desflurane is combined with Telmisartan. Approved, Investigational Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Desflurane. Approved, Investigational Terazosin The risk or severity of adverse effects can be increased when Desflurane is combined with Terazosin. Approved Terbutaline The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Desflurane. Approved Terodiline The risk or severity of QTc prolongation can be increased when Desflurane is combined with Terodiline. Experimental Tetrabenazine Desflurane may increase the QTc-prolonging activities of Tetrabenazine. Approved, Investigational Tetracycline The risk or severity of adverse effects can be increased when Desflurane is combined with Tetracycline. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Desflurane is combined with Tetrahydropalmatine. Investigational Tetrodotoxin The risk or severity of adverse effects can be increased when Desflurane is combined with Tetrodotoxin. Investigational Thalidomide Desflurane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. Approved, Investigational, Withdrawn Thiamylal The risk or severity of adverse effects can be increased when Desflurane is combined with Thiamylal. Approved, Vet Approved Thiopental The risk or severity of adverse effects can be increased when Desflurane is combined with Thiopental. Approved, Vet Approved Thioridazine Desflurane may increase the QTc-prolonging activities of Thioridazine. Approved, Withdrawn Thiothixene The risk or severity of adverse effects can be increased when Desflurane is combined with Thiothixene. Approved Tiagabine The risk or severity of adverse effects can be increased when Desflurane is combined with Tiagabine. Approved, Investigational Tiapride The risk or severity of adverse effects can be increased when Desflurane is combined with Tiapride. Approved, Investigational Tiletamine The risk or severity of adverse effects can be increased when Desflurane is combined with Tiletamine. Vet Approved Tilidine The risk or severity of adverse effects can be increased when Desflurane is combined with Tilidine. Experimental Timolol The risk or severity of adverse effects can be increased when Desflurane is combined with Timolol. Approved Tizanidine The risk or severity of adverse effects can be increased when Desflurane is combined with Tizanidine. Approved, Investigational Tolazoline The risk or severity of adverse effects can be increased when Desflurane is combined with Tolazoline. Approved, Vet Approved Tolcapone The risk or severity of adverse effects can be increased when Desflurane is combined with Tolcapone. Approved, Withdrawn Topiramate The risk or severity of adverse effects can be increased when Desflurane is combined with Topiramate. Approved Torasemide The risk or severity of adverse effects can be increased when Desflurane is combined with Torasemide. Approved Toremifene Desflurane may increase the QTc-prolonging activities of Toremifene. Approved, Investigational Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Desflurane. Approved, Investigational Trandolapril The risk or severity of adverse effects can be increased when Desflurane is combined with Trandolapril. Approved Tranylcypromine Tranylcypromine may increase the orthostatic hypotensive activities of Desflurane. Approved, Investigational Trazodone The risk or severity of adverse effects can be increased when Desflurane is combined with Trazodone. Approved, Investigational Tretinoin The risk or severity of adverse effects can be increased when Desflurane is combined with Tretinoin. Approved, Investigational, Nutraceutical Triamterene The risk or severity of adverse effects can be increased when Desflurane is combined with Triamterene. Approved Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Desflurane. Approved, Investigational Tricaine methanesulfonate The risk or severity of adverse effects can be increased when Desflurane is combined with Tricaine methanesulfonate. Vet Approved Trichloroethylene The risk or severity of adverse effects can be increased when Desflurane is combined with Trichloroethylene. Approved Trifluoperazine The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Desflurane. Approved, Investigational Trifluperidol The risk or severity of adverse effects can be increased when Desflurane is combined with Trifluperidol. Experimental Triflupromazine The risk or severity of adverse effects can be increased when Desflurane is combined with Triflupromazine. Approved, Vet Approved Trimethadione The risk or severity of adverse effects can be increased when Desflurane is combined with Trimethadione. Approved Trimethoprim The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Desflurane. Approved, Vet Approved Trimipramine The risk or severity of adverse effects can be increased when Desflurane is combined with Trimipramine. Approved Triprolidine The risk or severity of adverse effects can be increased when Desflurane is combined with Triprolidine. Approved Valproic Acid The risk or severity of QTc prolongation can be increased when Desflurane is combined with Valproic Acid. Approved, Investigational Valsartan The risk or severity of adverse effects can be increased when Desflurane is combined with Valsartan. Approved, Investigational Vancomycin The risk or severity of adverse effects can be increased when Desflurane is combined with Vancomycin. Approved Vandetanib Desflurane may increase the QTc-prolonging activities of Vandetanib. Approved Vecuronium The risk or severity of adverse effects can be increased when Desflurane is combined with Vecuronium. Approved Vemurafenib Desflurane may increase the QTc-prolonging activities of Vemurafenib. Approved Venlafaxine The risk or severity of adverse effects can be increased when Desflurane is combined with Venlafaxine. Approved Veralipride The risk or severity of adverse effects can be increased when Desflurane is combined with Veralipride. Experimental Verapamil The risk or severity of adverse effects can be increased when Desflurane is combined with Verapamil. Approved Vigabatrin The risk or severity of adverse effects can be increased when Desflurane is combined with Vigabatrin. Approved Vinpocetine The risk or severity of adverse effects can be increased when Desflurane is combined with Vinpocetine. Investigational Vinyl ether The risk or severity of adverse effects can be increased when Desflurane is combined with Vinyl ether. Experimental Vortioxetine The risk or severity of adverse effects can be increased when Desflurane is combined with Vortioxetine. Approved, Investigational Xenon The risk or severity of adverse effects can be increased when Desflurane is combined with Xenon. Experimental Xylazine The risk or severity of adverse effects can be increased when Desflurane is combined with Xylazine. Vet Approved Yohimbine The risk or severity of adverse effects can be increased when Desflurane is combined with Yohimbine. Approved, Investigational, Vet Approved Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Desflurane. Approved, Illicit, Investigational Ziconotide The risk or severity of adverse effects can be increased when Desflurane is combined with Ziconotide. Approved Zimelidine The risk or severity of adverse effects can be increased when Desflurane is combined with Zimelidine. Withdrawn Ziprasidone Desflurane may increase the QTc-prolonging activities of Ziprasidone. Approved Zolazepam The risk or severity of adverse effects can be increased when Desflurane is combined with Zolazepam. Vet Approved Zolmitriptan The risk or severity of adverse effects can be increased when Desflurane is combined with Zolmitriptan. Approved, Investigational Zolpidem Desflurane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. Approved Zonisamide The risk or severity of adverse effects can be increased when Desflurane is combined with Zonisamide. Approved, Investigational Zopiclone The risk or severity of adverse effects can be increased when Desflurane is combined with Zopiclone. Approved Zotepine The risk or severity of adverse effects can be increased when Desflurane is combined with Zotepine. Approved, Investigational, Withdrawn Zuclopenthixol Desflurane may increase the QTc-prolonging activities of Zuclopenthixol. Approved, Investigational - Food Interactions
- Not Available
References
- Synthesis Reference
Leonid A. Rozov, Chialang Huang, Gerald G. Vernice, "Synthesis of desflurane." U.S. Patent US5205914, issued June, 1991.
US5205914- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015320
- KEGG Drug
- D00546
- KEGG Compound
- C07519
- PubChem Compound
- 42113
- PubChem Substance
- 46505270
- ChemSpider
- 38403
- ChEBI
- 4445
- ChEMBL
- CHEMBL1200733
- Therapeutic Targets Database
- DAP000693
- PharmGKB
- PA164749136
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Desflurane
- ATC Codes
- N01AB07 — Desflurane
- AHFS Codes
- 28:04.16 — Inhalation Anesthetics
- FDA label
- Download (174 KB)
- MSDS
- Download (51.1 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Baxter International Inc.
- General Injectables and Vaccines Inc.
- Dosage forms
Form Route Strength Liquid Respiratory (inhalation) 1.5 g/1mL Liquid Respiratory (inhalation) 100 % Liquid Respiratory (inhalation) 240 mL/240mL - Prices
Unit description Cost Unit Suprane inhalation liquid 0.76USD ml DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5617906 No 1994-10-08 2014-10-08 US
Properties
- State
- Liquid
- Experimental Properties
Property Value Source boiling point (°C) 23.5 °C Not Available water solubility Negligible Not Available logP 1.9 Not Available - Predicted Properties
Property Value Source Water Solubility 3.54 mg/mL ALOGPS logP 2.19 ALOGPS logP 2.4 ChemAxon logS -1.7 ALOGPS pKa (Strongest Acidic) 18.87 ChemAxon pKa (Strongest Basic) -4.8 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 1 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 9.23 Å2 ChemAxon Rotatable Bond Count 3 ChemAxon Refractivity 18.12 m3·mol-1 ChemAxon Polarizability 7.89 Å3 ChemAxon Number of Rings 0 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule Yes ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.9974 Blood Brain Barrier + 0.9941 Caco-2 permeable + 0.626 P-glycoprotein substrate Non-substrate 0.883 P-glycoprotein inhibitor I Non-inhibitor 0.9415 P-glycoprotein inhibitor II Non-inhibitor 0.9027 Renal organic cation transporter Non-inhibitor 0.9311 CYP450 2C9 substrate Non-substrate 0.8676 CYP450 2D6 substrate Non-substrate 0.919 CYP450 3A4 substrate Non-substrate 0.7556 CYP450 1A2 substrate Non-inhibitor 0.6194 CYP450 2C9 inhibitor Non-inhibitor 0.836 CYP450 2D6 inhibitor Non-inhibitor 0.9466 CYP450 2C19 inhibitor Non-inhibitor 0.707 CYP450 3A4 inhibitor Non-inhibitor 0.9604 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8921 Ames test Non AMES toxic 0.9042 Carcinogenicity Carcinogens 0.7045 Biodegradation Not ready biodegradable 0.9566 Rat acute toxicity 1.2690 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9724 hERG inhibition (predictor II) Non-inhibitor 0.909
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
- Kingdom
- Organic compounds
- Super Class
- Organohalogen compounds
- Class
- Organofluorides
- Sub Class
- Not Available
- Direct Parent
- Organofluorides
- Alternative Parents
- Organooxygen compounds / Hydrocarbon derivatives / Alkyl fluorides
- Substituents
- Organic oxygen compound / Hydrocarbon derivative / Organooxygen compound / Organofluoride / Alkyl halide / Alkyl fluoride / Aliphatic acyclic compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- organofluorine compound (CHEBI:4445)
Targets
- Kind
- Protein group
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Positive allosteric modulator
- General Function
- Inhibitory extracellular ligand-gated ion channel activity
- Specific Function
- Component of the heteropentameric receptor for GABA, the major inhibitory neurotransmitter in the vertebrate brain. Functions also as histamine receptor and mediates cellular responses to histamine...
Components:
References
- Mohler H, Fritschy JM, Rudolph U: A new benzodiazepine pharmacology. J Pharmacol Exp Ther. 2002 Jan;300(1):2-8. [PubMed:11752090]
- Riss J, Cloyd J, Gates J, Collins S: Benzodiazepines in epilepsy: pharmacology and pharmacokinetics. Acta Neurol Scand. 2008 Aug;118(2):69-86. doi: 10.1111/j.1600-0404.2008.01004.x. Epub 2008 Mar 31. [PubMed:18384456]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Transmitter-gated ion channel activity
- Specific Function
- The glycine receptor is a neurotransmitter-gated ion channel. Binding of glycine to its receptor increases the chloride conductance and thus produces hyperpolarization (inhibition of neuronal firing).
- Gene Name
- GLRA1
- Uniprot ID
- P23415
- Uniprot Name
- Glycine receptor subunit alpha-1
- Molecular Weight
- 52623.35 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Grasshoff C, Antkowiak B: Effects of isoflurane and enflurane on GABAA and glycine receptors contribute equally to depressant actions on spinal ventral horn neurones in rats. Br J Anaesth. 2006 Nov;97(5):687-94. Epub 2006 Sep 13. [PubMed:16973644]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Pdz domain binding
- Specific Function
- Ionotropic glutamate receptor. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. Binding of the excitatory neurotransmitter L-glutamate induces a co...
- Gene Name
- GRIA1
- Uniprot ID
- P42261
- Uniprot Name
- Glutamate receptor 1
- Molecular Weight
- 101505.245 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Dildy-Mayfield JE, Eger EI 2nd, Harris RA: Anesthetics produce subunit-selective actions on glutamate receptors. J Pharmacol Exp Ther. 1996 Mar;276(3):1058-65. [PubMed:8786535]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inducer
- General Function
- Voltage-gated potassium channel activity
- Specific Function
- Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the kidney (PubMed:1990381...
- Gene Name
- KCNA1
- Uniprot ID
- Q09470
- Uniprot Name
- Potassium voltage-gated channel subfamily A member 1
- Molecular Weight
- 56465.01 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Matchett GA, Allard MW, Martin RD, Zhang JH: Neuroprotective effect of volatile anesthetic agents: molecular mechanisms. Neurol Res. 2009 Mar;31(2):128-34. doi: 10.1179/174313209X393546. [PubMed:19298752]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Signal transducer activity
- Specific Function
- This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the transport of the calcium.
- Gene Name
- ATP2C1
- Uniprot ID
- P98194
- Uniprot Name
- Calcium-transporting ATPase type 2C member 1
- Molecular Weight
- 100576.42 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Other/unknown
- General Function
- Transporter activity
- Specific Function
- Mitochondrial membrane ATP synthase (F(1)F(0) ATP synthase or Complex V) produces ATP from ADP in the presence of a proton gradient across the membrane which is generated by electron transport comp...
- Gene Name
- ATP5D
- Uniprot ID
- P30049
- Uniprot Name
- ATP synthase subunit delta, mitochondrial
- Molecular Weight
- 17489.755 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kosk-Kosicka D, Roszczynska G: Inhibition of plasma membrane Ca(2+)-ATPase activity by volatile anesthetics. Anesthesiology. 1993 Oct;79(4):774-80. [PubMed:8214757]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Unknown
- General Function
- Nadh dehydrogenase (ubiquinone) activity
- Specific Function
- Core subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase (Complex I) that is believed to belong to the minimal assembly required for catalysis. Complex I functions in the tra...
- Gene Name
- MT-ND1
- Uniprot ID
- P03886
- Uniprot Name
- NADH-ubiquinone oxidoreductase chain 1
- Molecular Weight
- 35660.055 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Carriers
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
References
- Sawas AH, Pentyala SN, Rebecchi MJ: Binding of volatile anesthetics to serum albumin: measurements of enthalpy and solvent contributions. Biochemistry. 2004 Oct 5;43(39):12675-85. [PubMed:15449957]
Drug created on June 13, 2005 07:24 / Updated on September 17, 2018 20:52